Renal Replacement Therapies

2

Review clinical trials related to Renal Replacement Therapies. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Capital Offload-Shock

CAPITAL OFFLOAD-SHOCK will aim to answer if early use of renal replacement therapy, like dialysis, in patients with reduced body fluids causing the heart to be unable to pump enough blood through the body reduces in-hospital death when compared to the current standard of care. The current standard of care is to wait until renal replacement therapy is clinically necessary.

Participants needed: 456
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Ottawa Heart Institute Research CorporationUpdated: Sep 24, 2026Locations: 1
Eligibility criteria

adult patients >/= 18 years of age admitted to an intensive care unit [+2]

Patients whose care plan, as determined by the treating clinical team, will not... [+8]

Status: Not yet recruiting

French AKI Registry (FAKIR): A Multicenter Study on the In-Hospital Management and Outcomes of Severe Acute Kidney Injury in Nephrology Units

Acute Kidney Injury (AKI) is a common and serious condition in hospitalized patients, especially when it reaches stages 2 or 3 according to the KDIGO classification. These severe forms are associated with high mortality, a risk of progression to chronic kidney disease (CKD), and frequent cardiovascular complications. However, current data on how nephrologists manage these patients during hospitalization-and how these practices influence long-term outcomes-are limited and heterogeneous. The FAKIR study (French AKI Registry) is a prospective, multicenter, non-interventional observational study designed to describe the clinical management of patients admitted to nephrology departments for AKI stage 2 or 3 and to assess their renal and cardiovascular outcomes up to one year. The study hypothesizes that better characterization of in-hospital practices and patient trajectories will help identify predictors of renal recovery, progression to end-stage renal disease, and major cardiovascular events. Patients will be followed during hospitalization and at 3, 6, and 12 months to assess renal function, mortality, cardiovascular events, and rehospitalizations. This registry aims to provide real-life, multicenter data to support future guidelines and the development of structured post-AKI care pathways.

Participants needed: 750
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: University Hospital, Strasbourg, FranceUpdated: Aug 14, 2025
Eligibility criteria

Age ≥ 18 years at admission [+3]

AKI stage 1 only [+5]